Thousands of doses of AstraZeneca vaccines in Cyprus on Monday – See when vaccinations start

Cyprus will receive 7,200 doses of AstraZeneca vaccines next Monday and vaccinations will begin on Wednesday.

Information states that in February Cyprus will receive 70 thousand doses of AstraZeneca vaccines and in March another 70 to 100 thousand.

In the meantime, the Scientific Advisory Committee on Coronavirus recommended the administration of the AstraZeneca vaccine, without age limit, as the decision of Coreper, a competent authority in the European Union for the evaluation of scientific data and the licensing of medicinal products.

The reasons taken into account in the decision of the TEU were the scientific data and the recent publications that it had before it and concern the effectiveness of the vaccine, as well as the need to maximize the benefit and efficiency of the Vaccination Plan, following the official recommendation of Coreper.

Specifically, the following were taken into account:

1. Researchers' reports from the UK-based Medicines and Healthcare products Regulatory Agency (MHRA) acknowledged that the population over the age of 56 was underrepresented in the study to collect enough clinical efficacy data for older people, but opposed the fact that the immune antibody response in phases 1 and 2 was almost as good in people over 70 as in younger people. These data were also taken into account by Coreper, so that no age limit is submitted as a restriction on its administration.
2. The AstraZeneca vaccine is the only vaccine that, based on the results of clinical trials, may reduce the transmission of the virus.
3. Faster vaccination of people aged 65 and over as well as vulnerable groups, taking into account the availability of vaccines, will reduce morbidity and mortality, resulting in reduced hospitalization and burden on the Health System.

In addition, the recommendation of the Scientific Advisory Committee was adopted, that the 2nd dose of the vaccine be administered in the 12th week, taking into account the pre-publication of a study in the Lancet, with data collected from the United Kingdom, Brazil and South Africa. In this study it is noted that the effectiveness of the first dose of the vaccine after the 12th week increases on average to 82%, compared to the effectiveness of the first dose where for a period of less than 6 weeks the effectiveness of the vaccine averages 55% and between 6th and 8th week at 60%.

This proposal, which has been adopted by the Ministry of Health, continues the National Vaccination Plan as originally planned, a process that will allow faster vaccination protection for more people, especially population groups with an increased risk of chronic diseases. for serious illness.

More deaths from COVID-19 in Cyprus in January

Commission President and Commissioner Kyriakidou respond to criticism of vaccines

Johnson & Johnson has applied to the United States for authorization to use the single-dose vaccine